Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kashif Ali (NPI 1851423388)

Field	Value
Entity Type	Individual
Organization	Kashif Ali
Address	11886 Healing Way Ste 701
City	Silver Spring
State	MD
ZIP	20904
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 11, 2007

Payer Source	Total Paid
Medicare	$3.6M
Medicaid	$0

Key Findings

KASHIF ALI is effectively a Medicare-focused Hematology & Oncology physician with $3.6M in lifetime Medicare revenue and no Medicaid billing on file, making the practice single‑payer in observable claims data. The absence of any Medicaid codes indicates payer mix is dominated by Medicare beneficiaries and drug-administered services reimbursed through Medicare Part B.

Revenue concentration is high: the top 3 Medicare codes by revenue account for 58.3% of this provider's total Medicare revenue, signaling dependence on a small set of high-cost oncology biologic administrations to drive the practice’s topline. Those top codes include J9299, J9271, and J9144, which together constitute a majority of reported Medicare revenue.

The code mix—heavy on high-cost injectable oncology agents such as J9299 (nivolumab), J9271 (pembrolizumab), J9144 (daratumumab), plus supportive/adjunct biologics like J0897 (denosumab) and J2506 (pegfilgrastim)—indicates an infusion-centric oncology practice that delivers frequent IV/subcutaneous biologic and chemotherapy therapies rather than a predominantly clinic‑visit or procedure-focused workload. E/M codes (99213, 99214, 99203) appear but contribute a much smaller share of revenue, consistent with treatment-focused operations.

Competitive standing for specific drugs shows mixed positioning: the provider ranks in the 92nd percentile nationally for J9299 (ranks #42 of 505), indicating notably above-typical national volume and making them a major national participant for nivolumab administration. For other top drugs, ranking varies from typical to highly concentrated: J9271 is at the 69th percentile (rank #576 of 1841), J9144 at the 75th percentile (rank #147 of 615), while J0897 and J0881 are described as extreme outliers or 100th percentile in national volume, suggesting unusually large volumes for denosumab and darbepoetin alfa relative to peers.

Several administration and infusion codes are extreme or notable outliers versus national peers: 99213 and 96372 are flagged as extreme outliers (100th and 99th percentiles respectively) and multiple infusion/administration codes such as 96413, 96365, 96367, 96375, and 96417 rank in high percentiles, reflecting very high throughput of infusion visits and supportive care injections compared with national providers. This pattern implies substantial on‑site infusion capacity and workflow optimized for frequent drug administration.

The provider’s NPI was enumerated on 2007-03-11, giving roughly 19 years of potential billing history; the longevity supports an established practice infrastructure capable of sustaining high-volume injectable therapy lines and repeat infusion encounters. This tenure, combined with the dominant Medicare revenue and concentrated biologics mix, suggests stable specialization in medical oncology services.

Operational risk and business implications: heavy reliance on high-cost biologic injectables (J9299, J9271, J9144) and a small number of codes producing the majority of revenue could make the practice sensitive to drug utilization shifts, payment policy changes, or formulary impacts in Medicare Part B. Payers and network analysts should treat this provider as a high-volume infusion site where changes to reimbursement for these codes would meaningfully affect revenue.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

83 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	37,000	$20	$888K
J9271	Injection, pembrolizumab, 1 mg	16,700	$40	$668K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	12,060	$40	$446.2K
J0897	Injection, denosumab, 1 mg	23,940	$20	$430.9K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	119,150	$1	$238.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,620	$70	$116.8K
J1439	Injection, ferric carboxymaltose, 1 mg	113,250	$1	$113.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	760	$110	$84.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	710	$110	$75.4K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	740	$80	$59.5K

Showing 1–10 of 83

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 83 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Kashif Ali — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

83 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	27	60	15,000	$40	$787.6K
J9299	5	20	24,080	$20	$660.6K
J9144	14	30	11,970	$40	$493.5K
J0897	13	340	3,600	$20	$114.4K
J0881	1	60	30,420	$1	$76.4K
J1437	28	50	2,800	$20	$75.1K
J3490	7	100	70	$450	$62.1K
J2506	8	30	590	$80	$55.2K
J1439	2	40	30,750	$1	$36.2K
96413	13	230	200	$110	$29.6K

Showing 1–10 of 83

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kashif Ali, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Andrew Mener	MD	Hematology & Oncology Physician	$3.5M	$0
Jason Taksey	MD	Medical Oncology Physician	$3.3M	$0
Frederick Min	MD	Hematology & Oncology Physician	$3.2M	$0
Mohit Narang	MD	Medical Oncology Physician	$3M	$0
Frederick Smith	MD	Medical Oncology Physician	$2.7M	$0
Deepnarayan Tiwarri	MD	Hematology & Oncology Physician	$2.6M	$0
Amr Hegazi	MD	Hematology & Oncology Physician	$2.3M	$0
Edward Lee	MD	Medical Oncology Physician	$1.9M	$0
Ravin Garg	MD	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Kashif Ali, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Community Radiology Associates Inc	MD	Diagnostic Radiology Physician	$0	$27.8M
Mission Autism Clinics LLC	MD	Behavior Analyst	$0	$21.6M
Children's Pediatricians & Associates, LLC	MD	Pediatrics Physician	$0	$17.5M
Dr. Camps Pediatric Dental Center	MD	Pediatric Dentistry	$0	$16.1M
Thrive Behavioral Health, LLC	MD	Community/Behavioral Health Agency	$0	$12.8M
White Oak Pediatrics Drs Battiata & Impeduglia PA	MD	Pediatrics Physician	$0	$12.3M
Jsk Care Group, LLC	MD	Adult Day Care Clinic/Center	$0	$11.8M
Rock Creek Foundation For Mental Health Inc	MD	Developmental Disabilities Clinic/Center	$0	$10.2M
Adventist Healthcare, Inc.	MD	General Acute Care Hospital	$0	$4.5M
David Heydt	MD	Anatomic Pathology Physician	$1.1M	$0

Kashif Ali — Billing Profile & Reimbursement Data

Sign up for Kashif Ali — Billing Profile & Reimbursement Data policy alerts

Kashif Ali — Billing Profile & Reimbursement Data

Sign up for Kashif Ali — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References